MIRA

MIRA Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company's pipeline includes oral drug candidates designed to address significant unmet medical needs in neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline. It holds exclusive license rights in the United States, Canada and Mexico for Ketamir-2 and MIRA-55, two novel drug candidates designed to address unmet medical needs in neuropathic and inflammatory pain, as well as neuropsychiatric and neurocognitive disorders. Its pipeline also includes SKNY-1, a next-generation oral therapy candidate for obesity and smoking cessation. Ketamir-2 is a patent-pending oral ketamine analog evaluated for the treatment of diabetic neuropathy and is in an ongoing Phase I clinical trial.

Wall Street analysts forecast MIRA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MIRA is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

MIRA Pharmaceuticals Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

MIRA Pharmaceuticals Inc. EPS for the last quarter amounts to -1.18 USD, increased 742.86 % YoY.

MIRA Pharmaceuticals Inc (MIRA) has 3 emplpoyees as of December 17 2025.

Today MIRA has the market capitalization of 60.72M USD.